Akebia Therapeutics (AKBA) SEC Filings: History & Chart

Akebia Therapeutics, Inc.(AKBA)

Biotechnology · Waltham, MA

$0.88-0.03 (-3.17%)

Delayed quote: Oct 6, 2026, 1:50 PM EDT

About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.

Waltham, MA

194 employees

www.akebia.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John Butler

View full financials

Form	Filing Date	Accepted	Document
4	Aug 10, 2026	Aug 10, 2026	View filing
S-8	Aug 5, 2026	Aug 5, 2026	View filing
10-Q	Aug 5, 2026	Aug 5, 2026	View filing
8-K	Aug 5, 2026	Aug 5, 2026	View filing
4	Jul 1, 2026	Jul 1, 2026	View filing
8-K	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
8-K	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
SC 13G	May 12, 2026	May 12, 2026	View filing
10-Q	May 7, 2026	May 7, 2026	View filing
8-K	May 7, 2026	May 7, 2026	View filing
ARS	Apr 29, 2026	Apr 28, 2026	View filing
DEFA14A	Apr 28, 2026	Apr 28, 2026	View filing
DEF 14A	Apr 28, 2026	Apr 28, 2026	View filing
PRE 14A	Apr 15, 2026	Apr 15, 2026	View filing
4	Apr 3, 2026	Apr 3, 2026	View filing
3	Apr 3, 2026	Apr 3, 2026	View filing
8-K	Apr 1, 2026	Apr 1, 2026	View filing
SC 13G/A	Mar 26, 2026	Mar 26, 2026	View filing
4	Mar 5, 2026	Mar 5, 2026	View filing
10-K	Feb 26, 2026	Feb 26, 2026	View filing
8-K	Feb 26, 2026	Feb 26, 2026	View filing
SC 13G	Feb 9, 2026	Feb 9, 2026	View filing
4	Feb 4, 2026	Feb 4, 2026	View filing
4	Feb 4, 2026	Feb 4, 2026	View filing

SEC Filings

Recent Filings